CA2446615C - Nutritional composition for the treatment of connective tissue - Google Patents

Nutritional composition for the treatment of connective tissue Download PDF

Info

Publication number
CA2446615C
CA2446615C CA002446615A CA2446615A CA2446615C CA 2446615 C CA2446615 C CA 2446615C CA 002446615 A CA002446615 A CA 002446615A CA 2446615 A CA2446615 A CA 2446615A CA 2446615 C CA2446615 C CA 2446615C
Authority
CA
Canada
Prior art keywords
nutritional composition
composition according
glucosamine
collagen
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002446615A
Other languages
French (fr)
Other versions
CA2446615A1 (en
Inventor
George D. Petito
Anita M. Petito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/287,590 external-priority patent/US6645948B2/en
Application filed by Individual filed Critical Individual
Publication of CA2446615A1 publication Critical patent/CA2446615A1/en
Application granted granted Critical
Publication of CA2446615C publication Critical patent/CA2446615C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nutritional composition for the treatment of connective tissue in mammals which includes a glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate which synergistically act as a chondroprotective agent. The composition can further include a detoxifying agent, an anti-inflammatory agent or an analgesic to demonstrate additional therapeutic and physiologic properties. The nutritional composition acts as a chondro-protective agent which provides foundational support for the creation of new body tissue and cartilage growth in humans and animals.

Description

NUTRITIONAL COMPOSITION FOR THE TREATMENT OF CONNECTIVE TISSUE
BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

The present invention relates to therapeutic compositions which provide for the treatment of connective tissue in mammals and, more particularly to nutritional compositions capable of acting as chondroprotective agents, as well as exhibiting added pharmacological properties.
2. DESCRIPTION OF THE RELATED ART

The related art of interest discloses numerous pharmaceutical compositions and methods for the treatment of connective tissue in humans and animals. For example, U.S. Patent No. 4,837,024 issued on June 6, 1989, to Dov Michaeli describes topical compositions for improving wound healing comprising a suspension of particles of collagen and a glycosaminoglycan. The composition is taught to be useful for treating surface wounds by applying the composition to a gauze, bandage or the like.

U.S. Patent No. 4,216,204 issued on August 5, 1980, and U.S.
Patent No. 4,455,302 issued on June 19, 1984, to Harry J. Robertson both disclose a medical protein hydrolysate containing an acetic acid extract of polypeptides and amino acids in the form of powder or a gel and produced from poultry feet. An aqueous solution can also be injected into a wound area such as burned animal regions.
The composition is described as being useful for regrowing muscle, skin and nerve tissue.

U.S. Patent No. 5,141,928 issued on August 25, 1992, to Lawrence Goldman describes ophthalmic medications containing glycosaminoglycan polysulfates (GAGPS) or mucopolysaccharides having a molecular weight in the range of 5,000 to 20,000 Daltons combined with antibiotics for treating eye infections and antimicrobial agents such as pilocarpine or epinephrine for glaucoma. GAGPS include chondroitin sulfate and hyaluronic acid that contain hexosamines.

U.S. Patent No. 5,840,715 issued on November 24, 1998 to Vito Florio teaches a dietary regimen of nutritional supplements for relief of symptoms of arthritis. The dietary regimen comprises gamma linolenic acid (GLA), a mixture of eicosapentaenoic acid and docosahexaneoic acid (EPA) and a mixture of chondroitin sulfate, glucosamine sulfate and manganese asparate.

U.S. Patent No. 5,442,053 issued on August 15, 1995, to Francesco della Valle et al. describes a pharmaceutical composition and method for treating ophthalmic and dermatological conditions, diseases of the oral and nasal cavities or diseases of the outer ear by administering a salt of hyaluronic acid (alkali, alkali metal, magnesium, aluminum or ammonium) combined with a pharmacologically active substance such as erythromycin. The hyaluronic acid fraction has an average molecular weight of 30,000 to 730,000. The topical medicament can be applied as solids or in solution.

U.K. Patent Application No. 896,940 published on May 23, 1962, to Chas. Pfizer & Co. describes a healing agent for wounds of the body surface containing glucosamine and/or N-acetylglucosamine and glucosamine phosphate in. a saline solution It has further been suggested by various prior art disclosures to use exclusively "nutraceuceuticals" or compositions containing only naturally-occurring components for treating connective tissue afflictions. For example, U.S. Patent Nos. 5,364,845 issued on November 15, 1994 and 5,587,363 issued December 24, 1996, both to Robert W. Henderson describe therapeutic compositions administered in capsules form for the protection, treatment and repair of connective tissue in mammals. The compositions contain 250-3000 mg glucosamine hydrochloride or sulfate, 50-1000 mg chondroitin sulfate, and can additionally comprise 15-950 mg manganese ascorbate.

In other related art, Body Ammo Nutraceuticals in a "Product Alert" article, published October 27, 1997, discloses capsules containing curcumin, hyaluronic acid, chondroitin sulfate and glucosamine. This product is stated to provide nutritional support for connective tissue. Further, Richardson Labs, Inc. in a "Lookout (Non Foods Edition)" abstract, published September 9, 1997, discloses a product described as a food supplement containing hydrolyzed collagen, glucosamine and chondrotin sulfate that is described as being capable of reconstructing bone cartilage.

U.S. Patent No. 5,929,050 issued on July 27, 1999 to George D. Petito discloses a method and composition for treating open wounds by applying to the wound an effective amount of an aqueous solution of chrondroitin sulfate, which may optionally include collagen, sodium hyaluronate and/or glucosamine hydrochloride.

While all the above references have been described as being effective for their intended use, there remains a need in the art for a therapeutic composition which demonstrates enhanced effectiveness in the treatment of connective tissues, exhibits other improved beneficial properties, and provides even wider applications in the modes of administration. The present invention meets these needs.
3 SUMMARY OF THE INVENTION
The present invention is a nutritional composition for the treatment of connective tissue in mammals. The nutritional composition includes: a therapeutically effective amount of a glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is an improvement over the compositions set forth in U.S. Patent No. 6,476,005, issued November 5, 2002. Thus, the present invention is directed to a nutritional composition comprising a therapeutically effective amount of a chondroprotective agent, preferably in combination with at least one other physiologically beneficial agent. The nutritional compositions include a therapeutically effective amount of a glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate which synergistically act as a chondroprotecetive agent. The nutritional compositions of the present invention are capable of being formulated into powder, capsule or tablet form for oral ingestion. The present compositions can also be prepared as a gel, paste or cream for topical application, or in a solution or suitable pharmaceutical carrier for oral or parenteral administration. Preferably, a detoxifying agent, an anti-inflammatory agent and/or an analgesic is incorporated into the formulations to provide added beneficial therapeutic and physiologic properties to the present compositions.
The present nutritional composition comprises about 1-30 mg/kg of a glucosamine salt, about 1-15 mg/kg of chondroitin sulfate, about 1-30 mg/kg of collagen and about 1-15 mg/kg of sodium
4 hyaluronate which synergistically act as the chondroprotective agent, wherein the dosage of each solid component present in the composition is expressed herein in terms of mg per kg bodyweight of the human to be treated. The unit dosages of the present compositions for animals may be substantially larger.

While the present compositions effectively provide foundational support for the creation of new body tissue and cartilage growth, facilitate chondrocyte synthesis, protect and maintain healthy muscle and tissue, increase hyaluronic acid concentrations, and reduce inflammation, other beneficial physiological properties of the compositions can be significantly enhanced by the incorporation of additional chemical agents.
Preferably, a detoxifying agent, an anti-inflammatory agent and/or an analgesic is added to the present nutritional compositions for these intended purposes.

The glucosamine salt component of the present compositions is preferably the hydrochloride salt, but other salts of glucosamine such as the sulfate, nitrate or iodide obtained from either synthetic, bovine or porcine sources are also suitable. The chondroitin sulfate component may include Type A (chondroitin-4-sulfate), Type B (chrondroitin-5-sulfate), and/or Type C
(chondroitin-6-sulfate), obtained through fermentation or extraction of bovine trachea, other bovine or porcine sources. A
molecular weight range of 2,000-50,000 can be used, with a preferred range of 25,000-35,000. The sodium hyaluronate component of the present compositions are obtained from either synthetic, bovine or avian sources with a molecular weight range from about 50,000 to about 3,500,000 Daltons. Both the chrondroitin sulfate and sodium hyaluronate components are glycosaminoglycans, commonly known as mucopolysaccharides.

All types of collagen, including native as well as hydrolyzed collagen, obtained from synthetic, avian, bovine or porcine sources
5 would be suitable as the collagen component of the present compositions. The hydrolyzed collagen component can include hydrolyzed Type 1 collagen, preferably natural hydrolyzed collagen powder having a pH of 5.5-6.5, an ash content of 2.5% maximum, an isotonic point of 5.0-6.5. The hydrolyzed Type 1 collagen can have a molecular weight average up to 10,000 Daltons.

Other chemical agents which enhance the chondroprotective properties of the present nutritional compositions include a manganese salt and L-malic acid. A preferred salt is manganese ascorbate because it provides ascorbic acid for collagen synthesis, but other manganese salts such as the sulfate, nitrate, and gluconate can be used. The L-malic acid acts as a detoxifying agent by ridding the body of unwanted lactic acid, often found in connective tissue. Both the L-malic acid and manganese salt are preferably of U. S. P. food grade, and are present in the nutritional compositions of the present invention in dosages ranging from about 0.05 to about 8 mg/kg.

Pharmacological agents may be incorporated into the nutritional compositions of the present invention to significantly enhance the physiological properties of the compositions. The anti-inflammatory agents methy sulfonyl methane (Msrvt) and cetyl myristoleate may be added to reduce an inflammatory response. The MsM may be added in amounts of about 0.5-40 mg/kg, and cetyl myristoleate in amounts of 1-105 mg/kg. The present compositions may also be combined with aspirin, preferably in the range of about 0.1-35 mg/kg, and other commercially available analgesics to reduce pain. In addition, the incorporation of such vitamins as Vitamin C(ascorbic acid) and Vitamin B12 in the present compositions provides added benefits to soft and hard tissues.

The nutritional compositions of the present invention are formulated into powder, capsule or tablet form for oral ingestion.
Also, the present compositions are capable of being combined with
6 a suitable pharmaceutical carrier and prepared as a gel, paste or cream for topical application. Alternatively, the compositions can be formulated in a solution or suitable pharmaceutical diluent for oral as well as parenteral administration.

For parenteral administration, the present compositions are preferably dissolved in sterilized water and buffered with such buffering agents as citric acid or sodium chloride to improve shelf life. The pH of the present solutions can be adjusted with conventional agents. Also, preservatives such as ethylene-diaminetetraacetic acid. (EDTA), benzyl alcohol, and benzalkonium chloride can be added.

The nutritional compositions of the present invention provide an enhanced chondroprotective effect by providing foundational support for the creation of new body tissue and cartilage growth in mammals. The collagen component act:s as a transporter or carrier for the larger molecules of sodium hyaluronate and/or chondroitin sulfate by aiding in the absorption process of these large molecules, thereby increasing the bio-availability of these therapeutic effective components.

The preferred embodiments of the invention provide therapeutic compositions that are not only capable of effectively treating connective tissues in mammals, but demonstrate other beneficial physiological properties as well. The preferred embodiments include nutritional compositions for the treatment of connective tissues in humans and animals which can be formulated into various pharmaceutical dosage forms for oral, topical and parenteral administration. The nutritional compositions include chondroprotective agents which provide foundational support for the creation of new body tissue and cartilage growth in humans and animals. The nutritional compositions promote the healing of wounds in humans and animals, while reducing the associated pain and inflammation.
7 It is to be understood that the present invention is not limited to the embodiments described above, but encompasses any and all embodiments within the scope of the following claims.
8

Claims (19)

CLAIMS:
1. A nutritional composition for connective tissue in mammals comprising: a glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate.
2. The nutritional composition according to claim 1, wherein the glucosamine salt is selected from the group consisting of glucosamine hydrochloride, glucosamine sulfate, glucosamine nitrate and glucosamine iodide.
3. The nutritional composition according to claim 1, wherein the collagen is hydrolyzed collagen.
4. The nutritional composition according to claim 3, wherein the hydrolyzed collagen is hydrolyzed Type 1 collagen having a molecular weight average up to 10,000 Daltons.
5. The nutritional composition according to claim 1, further comprising a manganese salt.
6. The nutritional composition according to claim 5, wherein the manganese salt is manganese ascorbate.
7. The nutritional composition according to claim 1, further comprising a detoxifying agent.
8. The nutritional composition according to claim 7, wherein the detoxifying agent is L-malic acid.
9. The nutritional composition according to claim 1, further comprising an anti-inflammatory agent.
10. The nutritional composition according to claim 9, wherein the anti-inflammatory agent is selected from the group consisting of methy sulfonyl methane and cetyl myristoleate.
11. The nutritional composition according to claim 1, further comprising an analgesic.
12. The nutritional composition according to claim 11, wherein the analgesic is aspirin.
13. The nutritional composition according to claim 1, further comprising a vitamin selected from the group consisting of Vitamin C and Vitamin B12.
14. The nutritional composition according to claim 1, wherein the composition is formulated into a unit dosage form for oral administration.
15. The nutritional composition according to claim 1, wherein the composition is combined with a suitable pharmaceutical carrier and prepared as a gel, paste or cream for topical application.
16. The nutritional composition according to claim 1, wherein the composition is formulated in a solution or suitable pharmaceutical diluent for oral or parenteral administration.
17. The nutritional composition according to claim 1, wherein the composition comprises, based on mg/kg of bodyweight:

about 1-30 mg/kg of a glucosamine salt;
about 1-15 mg/kg of chondroitin sulfate;
about 1-30 mg/kg of collagen; and about 1-15 mg/kg of sodium hyaluronate.
18. The nutritional composition according to claim 17, further including a manganese salt ranging from about 0.05 to about 8 mg/kg.
19. The nutritional composition according to claim 17, further including L-malic acid ranging from about 0.05 to about 8 mg/kg.
CA002446615A 2002-11-05 2003-10-24 Nutritional composition for the treatment of connective tissue Expired - Lifetime CA2446615C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/287,590 2002-11-05
US10/287,590 US6645948B2 (en) 1998-03-24 2002-11-05 Nutritional composition for the treatment of connective tissue

Publications (2)

Publication Number Publication Date
CA2446615A1 CA2446615A1 (en) 2004-05-05
CA2446615C true CA2446615C (en) 2009-02-03

Family

ID=32467733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446615A Expired - Lifetime CA2446615C (en) 2002-11-05 2003-10-24 Nutritional composition for the treatment of connective tissue

Country Status (1)

Country Link
CA (1) CA2446615C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918376B1 (en) 2007-07-04 2011-10-28 Mathieu Borge LIQUID OR PASSIZED COMPOSITIONS FOR THE CONTRIBUTION OF ESSENTIAL ELEMENTS TO THE SYNTHESIS AND CONSTITUTION OF PROTEOGLYCANS, IN PARTICULAR FOR THE TREATMENT OF CARTILAGE DEGRADATION

Also Published As

Publication number Publication date
CA2446615A1 (en) 2004-05-05

Similar Documents

Publication Publication Date Title
US6645948B2 (en) Nutritional composition for the treatment of connective tissue
US6476005B1 (en) Oral and injectable nutritional composition
AU747595B2 (en) Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and S-adenosylmethionine
US6583123B2 (en) Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
US6924273B2 (en) Chondroprotective/restorative compositions and methods of use thereof
US7091180B2 (en) Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US20020119952A1 (en) Composition and method of treating arthritis
AU7822798A (en) Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
KR20140108170A (en) Composition for maintaining effect of filler
AU767689B2 (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
US20030125303A1 (en) Transdermal formulation for repair and maintenance of connective tissue
CA2446615C (en) Nutritional composition for the treatment of connective tissue
GB2286528A (en) Dietary supplement
JP2001524080A (en) Composition comprising hydrolyzed collagen protein and glucosamine for the treatment of arthritis
RU2381029C1 (en) Combined chondroprotective pharmaceutical composition
US20050070500A1 (en) Method of modulating release of saccharides and uses thereof
US20240207351A1 (en) Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen
US20230310538A1 (en) Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen
US20240325503A1 (en) Wound healing and tissue repair composition and method using low molecular weight collagen and bioactive glass
Petito The Role of hyCURE® and Other Chondroprotective Agents in Oral Dietary Supplements

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231024